CNS 5161

Drug Profile

CNS 5161

Latest Information Update: 26 May 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CeNeS Pharmaceuticals
  • Class Guanidines; Sulfhydryl compounds
  • Mechanism of Action Glutamate receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer pain; Neuropathic pain

Most Recent Events

  • 31 Mar 2010 Discontinued - Phase-II for Cancer pain in Europe (IV)
  • 31 Mar 2010 Discontinued - Phase-II for Neuropathic pain in Europe (IV)
  • 31 Mar 2010 Discontinued - Preclinical for Neuropathic pain in United Kingdom (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top